PitchSend

Investor Presentaiton

8 Conclusion The results of the current study demonstrate that the potent GH receptor antagonist activity exhibited by AZP-3813 translates to effective, sustained in vivo suppression of IGF1 levels in normal Beagle dogs, and further support the development of AZP-3813 as a potential therapy for acromegaly For more detail, please visit our poster: RC 7.3 AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Effectively Suppresses IGF1 in Beagle Dogs Guillaume Ravel¹, Clémentine Chalmey¹, Corentin Berardet¹, David Duracher¹, Haruaki Kurasaki², Tatsuya Tomiyama², Patrick Reid², Michael D. Culler¹ AMOLYT PHARM A

View entire presentation